The global antibody drug conjugates market size is expected to be worth around US$ 10.93 billion by 2030, according to a new report by Vision Research Reports.
The global antibody drug conjugates market size is expected to be worth around US$ 10.93 billion by 2030, according to a new report by Vision Research Reports.
The global antibody drug conjugates market size was valued at US$ 2.57 billion in 2020 and is anticipated to grow at a CAGR of 35.9% during forecast period 2021 to 2030.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/37297
Growth Factors
Increasing incidence of cancer coupled with growing geriatric population are likely to drive the market for Antibody-Drug Conjugates (ADC). Furthermore, major technological advancements are also contributing to drive the growth. According to the World Health Organization (WHO), the number of people aged 65 years and above, is projected to reach 16% of the total population by 2050 from 7% in 2000. Aging has become a substantial risk factor for numerous diseases including cancer and others. Hence, the growing geriatric population is expected to drive growth of the market over the forecast period.
Until 2018, four ADCs were available in the market, namely, Adcetris, Kadcyla, Besponsa, and Mylotarg. Due to appropriate targeting and improved technology, ADCs have been gaining a lot of attention from both small and large pharmaceutical companies. Currently there are more than 50 ADCs in clinical trials and it has been projected that during the forecast period three to four ADCs will be commercialized in the area of refractory Hodgkin lymphoma, glioblastoma, small cell lung cancer, breast cancer, and ovarian cancer. It has been observed that the maximum number of clinical trials are being conducted for lymphoma.
| Report Coverage | Details |
| Market Size | US$ 10.93 billion by 2030 |
| Growth Rate | CAGR of 35.9% From 2021 to 2030 |
| Base Year | 2020 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Application, Technology |
| Regional Scope | North America, Latin America, Europe, Asia Pacific, MEA |
| Companies Mentioned | Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Pfizer, Inc.; AstraZeneca; Gilead Sciences, Inc.; Astellas Pharma; Seagen, Inc.; Daiichi Sankyo Company Ltd.; GlaxoSmithKline Plc; ADC Therapeutics |
Report Highlights
ADCs combine the sensitive and unique targeting abilities of antibodies which allows sensitive discrimination between cancer tissues and healthy tissues with the cell-killing ability of cytotoxic drugs. All the four ADCs available in the market are approved for the treatment of cancer.
Based on application, the market is categorized into blood cancer, breast cancer, ovarian cancer, lung cancer, and brain tumor. Breast cancer was the largest revenue generating segment in 2017 owing to the factors, such as high prevalence of breast cancer on global scale and commercial availability of Kadcyla in most of the major regions.
Rising prevalence of cancer is one of the major drivers accelerating the antibody drug conjugates market. According to the World Health Organization(WHO), in 2018, the most common types of cancer were breast cancer with 2.09 million cases, lung cancer with 2.09 million cases, colorectal cancer with 1.80 million cases, prostate cancer with 1.28 million cases, skin cancer with 1.04 million cases, and stomach cancer with 1.03 million cases.
Based on technology, the market is bifurcated into cleavable and non-cleavable linkers. These two are the most predominant technologies used to link cytotoxic anticancer agents’ payloads. For instance, two of the bestselling ADCs- Adcetris and Kadcyla, contains cleavable and non-cleavable linkers.
Production of suitable chemical linkers between the monoclonal antibody and the cytotoxic drug is one of the main challenges in manufacturing effective and safe ADCs. The synthesis of linker chemistry is relatively complex and numerous features must be balanced to guarantee efficacy, eventually, the type of linker being used forms the release profile of the cytotoxin.
North America was the largest revenue generating region, followed by Europe. The major factor attributing for their continued dominance includes the presence of significant market players, such as Seattle Genetics, Roche, Pfizer, and AbbVie. North America is the most well-established market in terms of the usage of ADCs coupled with well-established healthcare infrastructure, and patient awareness.
Key Players
Seattle Genetics, Inc.;Takeda Pharmaceutical Company Limited; Pfizer Inc.; F. Hoffmann-La Roche Ltd.; and AbbVie Inc.
Related Reports
- Peptide Drug Conjugates Market Report 2022-2030 - https://www.visionresearchreports.com/peptide-drug-conjugates-market/39800
- Custom Antibody Market Report 2022-2030 - https://www.visionresearchreports.com/custom-antibody-market/39762
- Antibody Fragments Market Report 2022-2030 - https://www.visionresearchreports.com/antibody-fragments-market/39596
Market Segmentation
- Application Outlook
- Blood Cancer
- Leukemia
- Lymphoma
- Breast Cancer
- Ovarian Cancer
- Lung Cancer
- Brain Tumor
- Blood Cancer
- Technology Outlook
- Cleavable Linker
- Non-cleavable Linker
- Regional Outlook
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/37297
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/